Ahmed Kotb/LinkedIn
Aug 18, 2025, 23:49
Ahmed Kotb: HHT Management—Choosing the Right Therapy?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“HHT management (guideline highlights):
- Epistaxis → Topical + Antifibrinolytics → Anti-angiogenic if refractory
- GI bleed → Grade by iron/RBC needs → (mild) → (moderate–severe)
- Anemia → Screen → Oral iron → IV iron.”
More on coagulation disorders featured in Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology